Quick Answer
Relay Therapeutics, Inc. reported Research And Development Expense of $99.86 million for the year ending 2020.
- Relay Therapeutics, Inc. showed an increase of +42.0% in Research And Development Expense from 2019 to 2020.
- This data is from Relay Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2021.
- XBRL data for this metric is available from 2019 to 2020 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $16.40 million | Q3 2019: $18.26 million | Q1 2020: $21.70 million | Q2 2020: $21.67 million | Q3 2020: $24.38 million | Q1 2021: $30.62 million.
- Historical annual values: Fiscal year 2020: $99.86 million | Fiscal year 2019: $70.31 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: